Cardiac Tissue Engineering Market Report 2026

The cardiac tissue engineering market size has grown rapidly in recent years. It will grow from $0.8 billion in 2025 to $0.96 billion in 2026 at a compound annual growth rate (CAGR) of 19.4%. The growth in the historic period can be attributed to advancements in stem cell research, increased prevalence of cardiovascular diseases, expansion of translational cardiac research programs, availability of advanced biomaterials, growth of academic-industry collaborations.

The cardiac tissue engineering market size is expected to see rapid growth in the next few years. It will grow to $1.92 billion in 2030 at a compound annual growth rate (CAGR) of 19%. The growth in the forecast period can be attributed to increasing investment in regenerative medicine, rising demand for alternatives to donor tissues, expansion of personalized cardiac therapies, growing clinical translation of engineered tissues, advancements in biofabrication techniques. Major trends in the forecast period include increasing development of tissue-engineered heart valves, rising use of stem cell-based cardiac therapies, growing adoption of advanced biomaterial scaffolds, expansion of regenerative approaches for myocardial repair, enhanced focus on functional tissue maturation.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the cardiac tissue engineering market in the coming years. Cardiac tissue engineering is an interdisciplinary field aimed at creating biological or bioartificial constructs to repair, regenerate, or replace damaged heart tissue. The rise in cardiovascular diseases is largely attributed to unhealthy lifestyle choices, such as poor diet, lack of physical activity, smoking, and growing rates of obesity and diabetes. Cardiac tissue engineering addresses cardiovascular diseases by developing biomaterials, cell-based therapies, and bioengineered tissues to restore damaged heart muscle and improve cardiac function. For example, in May 2023, the Centers for Disease Control and Prevention, a US governmental organization, reported that the percentage of coronary heart disease among female adults aged 18 and above slightly rose to 3.7% in 2023 from 3.6% in 2022. Consequently, the increasing prevalence of cardiovascular diseases is fueling the growth of the cardiac tissue engineering market.

The increasing healthcare expenditure is expected to drive the growth of the cardiac tissue engineering market in the coming years. Healthcare expenditure refers to the total financial resources utilized by individuals, organizations, or governments for preventing, treating, and managing health conditions. Spending on healthcare is rising due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, resulting in greater overall healthcare spending. Higher healthcare expenditure supports cardiac tissue engineering by funding research, clinical trials, infrastructure, and the adoption of regenerative heart therapies. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a U.S.-based agency responsible for administering the Medicare and Medicaid programs, U.S. healthcare expenditures increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Consequently, the rising healthcare expenditure is contributing to the growth of the cardiac tissue engineering market.

In April 2024, Valo Health LLC, a US-based technology company, acquired TARA Biosystems Inc. for an undisclosed sum. Through this acquisition, Valo Health leverages TARA's proprietary human cardiac disease platform to accelerate the discovery of new therapies for cardiovascular diseases. TARA Biosystems Inc. is a US-based company focused on developing 3D-engineered cardiac tissue models for drug discovery and disease modeling.

Major companies operating in the cardiac tissue engineering market are Xeltis AG, Humacyte Inc., Carmat S.A., Artivion Inc., Tissue Regenix Group plc, Cytograft Tissue Engineering Inc., BioCardia Inc., Bioheart Inc., Cardio3 Biosciences, Osiris Therapeutics Inc., StemCells Inc., CorMatrix Cardiovascular Inc., Vascugen Inc., CellProthera S.A., Myocardial Solutions Inc., Vericel Corporation, Lineage Cell Therapeutics Inc., Pluristem Therapeutics Inc., Reva Medical Inc., SynCardia Systems Inc.

North America was the largest region in the cardiac tissue engineering market in 2025. The regions covered in the cardiac tissue engineering market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac tissue engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cardiac tissue engineering market by increasing costs of imported biomaterials, laboratory instruments, bioreactors, and precision manufacturing equipment used in tissue fabrication and testing. Research institutions and biotech firms in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher costs in scaling pilot production facilities. These tariffs are increasing research and development expenditures and slowing commercialization timelines. At the same time, they are encouraging domestic biomaterial production, local manufacturing of lab equipment, and regional innovation ecosystems supporting cardiac regenerative technologies.

The cardiac tissue engineering market research report is one of a series of new reports that provides cardiac tissue engineering market statistics, including cardiac tissue engineering industry global market size, regional shares, competitors with a cardiac tissue engineering market share, detailed cardiac tissue engineering market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac tissue engineering industry. This cardiac tissue engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac tissue engineering involves using advanced biomedical techniques to develop functional heart tissue capable of repairing or regenerating damaged heart muscles. It combines cells, biomaterials, and bioactive factors to create engineered tissues that can restore cardiac function or support the treatment of heart diseases.

The primary products in cardiac tissue engineering include heart valves and vascular grafts. Heart valves are structures that control blood flow within the heart, ensuring it moves in the proper direction. The materials used include stem cells and scaffolds. The applications include treatment of myocardial infarction, heart valve repair or replacement, congenital heart disease management, and others. These products are utilized by hospitals and clinics, academic and research institutes, and other end users.

The cardiac tissue engineering market consists of revenues earned by entities by providing services such as the development of stem cell therapy and regeneration services, tissue engineering consultation and research services, and bioreactor and biomanufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac tissue engineering market includes sales of bioengineered cardiac tissues, biomaterials, cardiac tissue constructs, tissue scaffolds, bioactive molecules, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.